Description
Cancer Drug Design and Discovery, Second Edition is an important reference on the underlying principles for the design and subsequent development of new anticancer small molecule agents. New chapters have been added to this edition on areas of particular interest and therapeutic promise, including cancer genomics and personalized medicine, DNA-targeted agents and more. This book includes several sections on the basic and applied science of cancer drug discovery and features those drugs that are now approved for human use and are in the marketplace, as well as those that are still under development. By highlighting some of the general principles involved in taking molecules through basic science to clinical development, this book offers a complete and authoritative reference on the design and discovery of anticancer drugs for translational scientists and clinicians involved in cancer research.- Provides a clinical perspective on the development of new molecularly targeted anticancer agents with the latest and most promising chemotherapeutic approaches- Offers a broad view of where the field is going, what tools drug discovery is using to produce new agents and how they are evaluated in the laboratory and clinic- Features 6 new chapters devoted to advances in technology and successful anticancer therapies, such as cancer genomics and personalized medicine, DNA-targeted agents, B-Raf inhibitors and more- Each chapter includes extensive references to the primary and review literature, as well as to relevant web-based sources
Table of Contents
Introduction - Stephen NeidleForeword - Hilary CalvertPart I. Basic Principles and methodologyModern cancer drug discovery: integrating targets, technologies and treatments — Paul Workman andIan CollinsPharmacogenomics and personalised medicines in cancer treatment — Wei-Peng Yong, Ross Soo andFederico InnocentiStructural biology and anticancer drug design — Puja Pathuri, David Norton, Henriette Willems,Dominic Tisi and Harren JhotiPart II. Drugs in the laboratory and clinicTemozolomide: from cytotoxic to molecularly-targeted agent — Malcolm StevensTemozolomide: patents and the perils of invention — Malcolm StevensA new generation of cell-targeted drugs for cancer treatment — Paola B. Arimondo, Nicolas Guilbaudand Christian BaillyInhibition of DNA repair as a therapeutic target — Stephany Veuger and Nicola J CurtinInhibitors of tumour angiogenesis — Adrian L. Harris and Daniele G GeneraliThe Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer — Qingzhong Hu and RolfW. HartmannApoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting — Zahid H SiddikTargeting the MDM2-p53 protein-protein interaction: design, discovery and development of novelanticancer agents — Ian R HardcastleTargeting altered metabolism – emerging cancer therapeutic strategy — Minsuh Seo, Robert BlakeCrochet and Yong-Hwan LeeInhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway — William A Denny and Gordon W.RewcastleAntibody-drug conjugates delivering DNA cytotoxics — John A HartleyInhibition of telomerase: promise, progress and potential pitfalls — Christopher G. Tomlinson, Scott B.Cohen and Tracy M. BryanTargeting B-RAF: the discovery and development of B-RAF inhibitors — Phillip A HarrisPart III. The reality of cancer drugs in the clinicFailure Modes in Anticancer Drug Discovery and Development — Richard A. Walgren andChristopher. A. SlapakAnticancer drug registration and regulation: current challenges and possible solutions — DavidTaylor, Erling Donnelly and Silvia Chioato
